MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

<p>Abstract</p> <p>Background</p> <p>The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. O...

Full description

Bibliographic Details
Main Authors: Melguizo Consolación, Prados Jose, González Beatriz, Ortiz Raul, Concha Angel, Alvarez Pablo, Madeddu Roberto, Perazzoli Gloria, Oliver Jaime, López Rodrigo, Rodríguez-Serrano Fernando, Aránega Antonia
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Journal of Translational Medicine
Subjects:
Glioblastoma
Radiotherapy
Temozolomide
MGMT
Methylation
CD133
Online Access:http://www.translational-medicine.com/content/10/1/250

Internet

http://www.translational-medicine.com/content/10/1/250

Similar Items